glp-1 concerns Primer: The Skinny on GLP-1s Research shows GLP-1 receptor agonist

If anything is unclear, your dispensing pharmacy can confirm the correct handling for your particular order

Assessing the proportional hazards assumption, there was no significant interaction between follow-up time and use of GLP1 receptor agonists (P=0.82)

1 Of the 145,410 patients treated with GLP1 and 291,667 treated with dipeptidyl peptidase 4 (DPP4) inhibitor treatment, 76 and 184, respectively, developed thyroid cancer

Avoiding tanning beds is an easy step, as is wearing sunscreen year-round

In 2025, ongoing trials are evaluating whether MEK inhibition can delay or prevent malignant transformation, or serve as a neoadjuvant strategy to shrink MPNST prior to surgery (Gross et al., 2024)